论文部分内容阅读
欧洲共同体专性医药产品委员会(相当于美国食品和药物管理局)今年5月于布鲁塞尔提议批准重组白细胞介素-2作为治疗肾癌的药物。Cetus公司的欧洲分公司EuroCetus(阿姆斯特丹)在去年4月提出有关白细胞介素类似物Proleukin的申请。同年11月,Cetus要求美国食品和药物管理局批准Proleukin在美国的销售权。在5月份举行的美国临床癌学会(ASCO)年会上,报告了欧洲应用Proleukin治疗肾细胞癌的临床经验。法国里昂输血中心T.philip教授描述了分布于比利时、意大利、荷兰、挪威的95名患者,声称这些患者均产生“有意义的反应”,在传播了肿瘤的脏器——
The Commission of the European Community’s Specialized Pharmaceutical Products (equivalent to the US Food and Drug Administration) proposed in Brussels in May this year that recombinant interleukin-2 be used as a drug for the treatment of kidney cancer. Cetus Europe’s EuroCetus (Amsterdam) filed an application for the Proleukin, an analog of the interleukin, in April last year. In November of the same year, Cetus asked the US Food and Drug Administration to approve the sale of Proleukin in the United States. At the annual meeting of the American Society of Clinical Cancer (ASCO) held in May, the European experience with Proleukin in the treatment of renal cell carcinoma was reported. Prof. T. philip from Transfusion Center of Lyon, France, described 95 patients in Belgium, Italy, the Netherlands, and Norway. They claimed that these patients all had a “significant response” and transmitted tumor organs.